New mRNA shingles vaccine enters human trials
NCT ID NCT07400003
First seen Feb 18, 2026 · Last updated May 22, 2026 · Updated 15 times
Summary
This study is testing a new mRNA vaccine designed to prevent shingles (herpes zoster) in adults aged 40 and older. The trial has two parts: Part A checks safety and immune response in people 40+, and Part B picks the best dose and schedule for those 50+. Around 519 volunteers will receive either the vaccine or a placebo to see how well it works and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention
RECRUITINGXinjiang, 831100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.